SNORD114-15: A Non-Coding RNA Molecule as A Potential Drug Target Or Biomarker

Target Name: SNORD114-15

NCBI ID: G767593

SNORD114-15

Other Name(s): 14q(II-15) | small nucleolar RNA, C/D box 114-15 | Small nucleolar RNA, C/D box 114-15

SNORD114-15: A Non-Coding RNA Molecule as A Potential Drug Target Or Biomarker

SNORD114-15 (14q(II-15)) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer. Its unique structure and expression pattern have made it an attractive target for researchers to investigate, and various studies have shed light on its role in various biological processes.

SNORD114-15 is a RNA molecule that is located on chromosome 14, specifically on the inversion of exon II on the 15th chromosome. It is characterized by a unique structure, with a 5' end that is consist of a single RNA molecule, and a 3' end that contains a series of seven conserved domains, including a double-stranded loop, a stem-loop, and a tail.

One of the most significant features of SNORD114-15 is its expression pattern. It is expressed in a variety of tissues and cells throughout the body, including the brain, heart, liver, and various cancers. Its expression level is also known to be regulated by various factors, such as growth factors, chemokines, and DNA methylation.

In addition to its expression pattern, SNORD114-15 has also been shown to play a role in various biological processes. For example, it has been shown to be involved in the regulation of gene expression, specifically in the control of cell proliferation and differentiation. It has also been shown to play a role in the regulation of cell signaling pathways, including the TGF-β pathway.

The potential drug target status of SNORD114-15 is due to several reasons. First, its unique structure and expression pattern make it an attractive target for researchers to investigate the mechanisms of its function. Second, its expression pattern allows it to be easily targeted by small molecules, making it a potential drug candidate. Third, its involvement in various biological processes makes it a promising biomarker for the diagnosis and treatment of various diseases.

One of the most promising aspects of SNORD114-15 is its potential as a drug target for cancer. Cancer is a leading cause of death worldwide, and there is a significant need for new and effective treatments. SNORD114-15 has been shown to be involved in the regulation of cell proliferation and differentiation, which are key processes in cancer development. Therefore, it is a promising target for cancer therapies that aim to inhibit these processes.

In addition to its potential as a cancer drug target, SNORD114-15 has also been shown to be involved in the regulation of other biological processes, including cell signaling pathways. Its involvement in these processes makes it a potential candidate for the regulation of other diseases , including neurological and psychiatric disorders.

In conclusion, SNORD114-15 is a non-coding RNA molecule that has unique structure and expression pattern. Its potential as a drug target or biomarker makes it an attractive target for researchers to investigate the mechanisms of its function. Further studies are needed to fully understand its role in various biological processes and its potential as a drug target or biomarker.

Protein Name: Small Nucleolar RNA, C/D Box 114-15

The "SNORD114-15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD114-15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets